Last €56.14 EUR
Change Today -0.247 / -0.44%
Volume 0.0
ZEGA On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 9:39 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc-spons adr (ZEGA) Snapshot

Open
€56.22
Previous Close
€56.38
Day High
€56.63
Day Low
€56.14
52 Week High
05/2/14 - €59.21
52 Week Low
10/10/13 - €36.43
Market Cap
70.9B
Average Volume 10 Days
14.4
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/14
P/E TM
--
Dividend
€1.70
Dividend Yield
3.66%
Current Stock Chart for ASTRAZENECA PLC-SPONS ADR (ZEGA)

astrazeneca plc-spons adr (ZEGA) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc-spons adr (ZEGA) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc-spons adr (ZEGA) Key Developments

AstraZeneca Announces Committee for Medicinal Products for Human Use Approves MOVENTIG

AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of MOVENTIG (naloxegol), an investigational, peripherally-acting mu-opioid receptor antagonist (PAMORA), for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). OIC is a condition caused by prescription opioid pain medicines. Opioids work by binding to mu-receptors in the central nervous system, but they also bind to mu-receptors in the gastrointestinal tract, which can result in patients suffering from OIC. The positive opinion was reached after a review of comprehensive data from the KODIAC clinical programme comprised of four studies assessing the safety and efficacy of MOVENTIG. The CHMP's positive opinion on MOVENTIG will be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway. Should the EC approve MOVENTIG, it will be the first once-daily, oral PAMORA available in these markets for the treatment of OIC in adult patients who have had an inadequate response to laxative(s).

AstraZeneca PLC Presents at Öresund Investment Day- Life Science/Food, Sep-22-2014 03:00 PM

AstraZeneca PLC Presents at Öresund Investment Day- Life Science/Food, Sep-22-2014 03:00 PM. Venue: Medicon Village, Hörsalen, Scheelevägen 2, 223 63 Lund, Sweden. Speakers: Jens Lindberg, IR.

AstraZeneca Announces 28 Week Results from DURATION-NEO-1

AstraZeneca announced 28-week results from DURATION-NEO-1, a Phase III study comparing an investigational formulation of exenatide once-weekly suspension for autoinjection to twice-daily exenatide (Byetta) injection in adult patients with type 2 diabetes who had inadequate glycaemic control. The study met its primary endpoint of non-inferiority, demonstrating that exenatide once-weekly suspension for autoinjection provided greater mean reductions in HbA1c (blood glucose levels) compared to Byetta at 28 weeks (-1.4% vs. -1.0%, respectively; p-value = 0.007).1,2 The results were presented at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEGA:GR €56.14 EUR -0.247

ZEGA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $57.23 USD -0.53
Bayer AG €110.46 EUR -0.25
Celgene Corp $93.43 USD -1.35
GlaxoSmithKline PLC 1,414 GBp +1.00
Novo Nordisk A/S kr283.80 DKK +1.80
View Industry Companies
 

Industry Analysis

ZEGA

Industry Average

Valuation ZEGA Industry Range
Price/Earnings 44.9x
Price/Sales 3.5x
Price/Book 4.1x
Price/Cash Flow 45.0x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.